4u2x › Citations

Ebola virus VP24 targets a unique NLS binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated STAT1.

Xu W, Edwards MR, Borek DM, Feagins AR, Mittal A, Alinger JB, Berry KN, Yen B, Hamilton J, Brett TJ, Pappu RV, Leung DW, Basler CF, Amarasinghe GK
Cell Host Microbe 16 187-200 (2014)
Cited: 140 times
EuropePMC logo PMID: 25121748

Abstract

During antiviral defense, interferon (IFN) signaling triggers nuclear transport of tyrosine-phosphorylated STAT1 (PY-STAT1), which occurs via a subset of karyopherin alpha (KPNA) nuclear transporters. Many viruses, including Ebola virus, actively antagonize STAT1 signaling to counteract the antiviral effects of IFN. Ebola virus VP24 protein (eVP24) binds KPNA to inhibit PY-STAT1 nuclear transport and render cells refractory to IFNs. We describe the structure of human KPNA5 C terminus in complex with eVP24. In the complex, eVP24 recognizes a unique nonclassical nuclear localization signal (NLS) binding site on KPNA5 that is necessary for efficient PY-STAT1 nuclear transport. eVP24 binds KPNA5 with very high affinity to effectively compete with and inhibit PY-STAT1 nuclear transport. In contrast, eVP24 binding does not affect the transport of classical NLS cargo. Thus, eVP24 counters cell-intrinsic innate immunity by selectively targeting PY-STAT1 nuclear import while leaving the transport of other cargo that may be required for viral replication unaffected.

Reviews - 4u2x mentioned but not cited (4)

  1. Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus. Messaoudi I, Amarasinghe GK, Basler CF. Nat Rev Microbiol 13 663-676 (2015)
  2. Diversification of importin-α isoforms in cellular trafficking and disease states. Pumroy RA, Cingolani G. Biochem J 466 13-28 (2015)
  3. Molecular Mechanisms of Innate Immune Inhibition by Non-Segmented Negative-Sense RNA Viruses. Chatterjee S, Basler CF, Amarasinghe GK, Leung DW. J Mol Biol 428 3467-3482 (2016)
  4. Viral Targeting of Importin Alpha-Mediated Nuclear Import to Block Innate Immunity. Vogel OA, Forwood JK, Leung DW, Amarasinghe GK, Basler CF. Cells 13 71 (2023)

Articles - 4u2x mentioned but not cited (11)

  1. Ebola virus VP24 targets a unique NLS binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated STAT1. Xu W, Edwards MR, Borek DM, Feagins AR, Mittal A, Alinger JB, Berry KN, Yen B, Hamilton J, Brett TJ, Pappu RV, Leung DW, Basler CF, Amarasinghe GK. Cell Host Microbe 16 187-200 (2014)
  2. Quercetin Blocks Ebola Virus Infection by Counteracting the VP24 Interferon-Inhibitory Function. Fanunza E, Iampietro M, Distinto S, Corona A, Quartu M, Maccioni E, Horvat B, Tramontano E. Antimicrob Agents Chemother 64 e00530-20 (2020)
  3. Conserved differences in protein sequence determine the human pathogenicity of Ebolaviruses. Pappalardo M, Juliá M, Howard MJ, Rossman JS, Michaelis M, Wass MN. Sci Rep 6 23743 (2016)
  4. VP24-Karyopherin Alpha Binding Affinities Differ between Ebolavirus Species, Influencing Interferon Inhibition and VP24 Stability. Schwarz TM, Edwards MR, Diederichs A, Alinger JB, Leung DW, Amarasinghe GK, Basler CF. J Virol 91 e01715-16 (2017)
  5. Predictive and comparative analysis of Ebolavirus proteins. Cong Q, Pei J, Grishin NV. Cell Cycle 14 2785-2797 (2015)
  6. Antiviral Agents Against Ebola Virus Infection: Repositioning Old Drugs and Finding Novel Small Molecules. Fanunza E, Frau A, Corona A, Tramontano E. Annu Rep Med Chem 51 135-173 (2018)
  7. Investigating Ebola virus pathogenicity using molecular dynamics. Pappalardo M, Collu F, Macpherson J, Michaelis M, Fraternali F, Wass MN. BMC Genomics 18 566 (2017)
  8. Characterizing alpha helical properties of Ebola viral proteins as potential targets for inhibition of alpha-helix mediated protein-protein interactions. Chakraborty S, Rao BJ, Asgeirsson B, Dandekar A. F1000Res 3 251 (2014)
  9. Evolutionary conservation of Ebola virus proteins predicts important functions at residue level. Arslan A, van Noort V. Bioinformatics 33 151-154 (2017)
  10. Identification of promising anti-EBOV inhibitors: de novo drug design, molecular docking and molecular dynamics studies. Mohamed EAR, Abdelwahab SF, Alqaisi AM, Nasr AMS, Hassan HA. R Soc Open Sci 9 220369 (2022)
  11. Integrated Network Pharmacology and Metabolomics Analysis to Reveal the Potential Mechanism of Siwu Paste on Aplastic Anemia Induced by Chemotherapy Drugs. He D, Dan W, Du Q, Shen BB, Chen L, Fang LZ, Kuang JJ, Tang CY, Cai P, Yu R, Zhang SH, Huang JH. Drug Des Devel Ther 16 1231-1254 (2022)


Reviews citing this publication (50)

  1. Ten Strategies of Interferon Evasion by Viruses. García-Sastre A. Cell Host Microbe 22 176-184 (2017)
  2. Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. Martines RB, Ng DL, Greer PW, Rollin PE, Zaki SR. J Pathol 235 153-174 (2015)
  3. The Pathogenesis of Ebola Virus Disease. Baseler L, Chertow DS, Johnson KM, Feldmann H, Morens DM. Annu Rev Pathol 12 387-418 (2017)
  4. Structural Biology and Regulation of Protein Import into the Nucleus. Christie M, Chang CW, Róna G, Smith KM, Stewart AG, Takeda AA, Fontes MR, Stewart M, Vértessy BG, Forwood JK, Kobe B. J Mol Biol 428 2060-2090 (2016)
  5. The molecular basis for functional plasticity in type I interferon signaling. Schreiber G, Piehler J. Trends Immunol 36 139-149 (2015)
  6. Potential and emerging treatment options for Ebola virus disease. Bishop BM. Ann Pharmacother 49 196-206 (2015)
  7. The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19. Schreiber G. Front Immunol 11 595739 (2020)
  8. Viral Inhibition of the IFN-Induced JAK/STAT Signalling Pathway: Development of Live Attenuated Vaccines by Mutation of Viral-Encoded IFN-Antagonists. Fleming SB. Vaccines (Basel) 4 E23 (2016)
  9. Immunobiology of Ebola and Lassa virus infections. Prescott JB, Marzi A, Safronetz D, Robertson SJ, Feldmann H, Best SM. Nat Rev Immunol 17 195-207 (2017)
  10. New paradigms in sepsis: from prevention to protection of failing microcirculation. Hawiger J, Veach RA, Zienkiewicz J. J Thromb Haemost 13 1743-1756 (2015)
  11. The Molecular Basis of Viral Inhibition of IRF- and STAT-Dependent Immune Responses. Chiang HS, Liu HM. Front Immunol 9 3086 (2018)
  12. The JAK-STAT pathway at 30: Much learned, much more to do. Philips RL, Wang Y, Cheon H, Kanno Y, Gadina M, Sartorelli V, Horvath CM, Darnell JE, Stark GR, O'Shea JJ. Cell 185 3857-3876 (2022)
  13. Camouflage and misdirection: the full-on assault of ebola virus disease. Misasi J, Sullivan NJ. Cell 159 477-486 (2014)
  14. Molecular pathogenesis of viral hemorrhagic fever. Basler CF. Semin Immunopathol 39 551-561 (2017)
  15. Karyopherin-mediated nucleocytoplasmic transport. Wing CE, Fung HYJ, Chook YM. Nat Rev Mol Cell Biol 23 307-328 (2022)
  16. Type I IFN family members: similarity, differences and interaction. Capobianchi MR, Uleri E, Caglioti C, Dolei A. Cytokine Growth Factor Rev 26 103-111 (2015)
  17. Subcellular Performance of Nanoparticles in Cancer Therapy. Liu CG, Han YH, Kankala RK, Wang SB, Chen AZ. Int J Nanomedicine 15 675-704 (2020)
  18. Rodent-Adapted Filoviruses and the Molecular Basis of Pathogenesis. Banadyga L, Dolan MA, Ebihara H. J Mol Biol 428 3449-3466 (2016)
  19. Ebolavirus Evolution: Past and Present. de La Vega MA, Stein D, Kobinger GP. PLoS Pathog 11 e1005221 (2015)
  20. Early IFN type I response: Learning from microbial evasion strategies. Coccia EM, Battistini A. Semin Immunol 27 85-101 (2015)
  21. Respiratory syncytial virus nonstructural proteins 1 and 2: Exceptional disrupters of innate immune responses. Sedeyn K, Schepens B, Saelens X. PLoS Pathog 15 e1007984 (2019)
  22. Ebola virus disease: a highly fatal infectious disease reemerging in West Africa. To KK, Chan JF, Tsang AK, Cheng VC, Yuen KY. Microbes Infect 17 84-97 (2015)
  23. Innate immune evasion by filoviruses. Basler CF. Virology 479-480 122-130 (2015)
  24. Signaling through RIG-I and type I interferon receptor: Immune activation by Newcastle disease virus in man versus immune evasion by Ebola virus (Review). Schirrmacher V. Int J Mol Med 36 3-10 (2015)
  25. Distinct Genome Replication and Transcription Strategies within the Growing Filovirus Family. Hume AJ, Mühlberger E. J Mol Biol 431 4290-4320 (2019)
  26. Filovirus Strategies to Escape Antiviral Responses. Olejnik J, Hume AJ, Leung DW, Amarasinghe GK, Basler CF, Mühlberger E. Curr Top Microbiol Immunol 411 293-322 (2017)
  27. Molecular mechanisms of Ebola pathogenesis. Rivera A, Messaoudi I. J Leukoc Biol 100 889-904 (2016)
  28. Nipah virus matrix protein: expert hacker of cellular machines. Watkinson RE, Lee B. FEBS Lett 590 2494-2511 (2016)
  29. An update on enterovirus 71 infection and interferon type I response. Rasti M, Khanbabaei H, Teimoori A, Teimoori A. Rev Med Virol 29 e2016 (2019)
  30. Crosstalk between nucleocytoplasmic trafficking and the innate immune response to viral infection. Shen Q, Wang YE, Palazzo AF. J Biol Chem 297 100856 (2021)
  31. Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients. Schirrmacher V. Int J Mol Sci 18 E1103 (2017)
  32. Roles of nuclear trafficking in infection by cytoplasmic negative-strand RNA viruses: paramyxoviruses and beyond. Audsley MD, Jans DA, Moseley GW. J Gen Virol 97 2463-2481 (2016)
  33. Current status of small molecule drug development for Ebola virus and other filoviruses. Edwards MR, Basler CF. Curr Opin Virol 35 42-56 (2019)
  34. Ebolaviruses: New roles for old proteins. Cantoni D, Rossman JS. PLoS Negl Trop Dis 12 e0006349 (2018)
  35. Antigenic Variation and Immune Escape in the MTBC. Ernst JD. Adv Exp Med Biol 1019 171-190 (2017)
  36. Implications of Toll-like receptors in Ebola infection. Saghazadeh A, Rezaei N. Expert Opin Ther Targets 21 415-425 (2017)
  37. Viral dedication to vigorous destruction of interferon receptors. Xia C, Anderson P, Hahm B. Virology 522 19-26 (2018)
  38. How SARS-CoV-2 and Other Viruses Build an Invasion Route to Hijack the Host Nucleocytoplasmic Trafficking System. Sajidah ES, Lim K, Wong RW. Cells 10 1424 (2021)
  39. Host Factors in Ebola Infection. Rasmussen AL. Annu Rev Genomics Hum Genet 17 333-351 (2016)
  40. Immunological Perspective for Ebola Virus Infection and Various Treatment Measures Taken to Fight the Disease. Jain S, Khaiboullina SF, Baranwal M. Pathogens 9 E850 (2020)
  41. Virus and host interactions critical for filoviral RNA synthesis as therapeutic targets. Basler CF, Krogan NJ, Leung DW, Amarasinghe GK. Antiviral Res 162 90-100 (2019)
  42. Structural and Functional Aspects of Ebola Virus Proteins. Jain S, Martynova E, Rizvanov A, Khaiboullina S, Baranwal M. Pathogens 10 1330 (2021)
  43. Nucleocytoplasmic Shuttling of STATs. A Target for Intervention? Ernst S, Müller-Newen G. Cancers (Basel) 11 E1815 (2019)
  44. A survey on Ebola genome and current trends in computational research on the Ebola virus. Dutta P, Halder AK, Basu S, Kundu M. Brief Funct Genomics 17 374-380 (2018)
  45. Ebolavirus interferon antagonists-protein interaction perspectives to combat pathogenesis. Banerjee A, Pal A, Pal D, Mitra P. Brief Funct Genomics 17 392-401 (2018)
  46. [Innate immunity evasion mechanisms of filoviruses]. Martin B, Decroly É. Med Sci (Paris) 34 671-677 (2018)
  47. Filoviruses: Innate Immunity, Inflammatory Cell Death, and Cytokines. Lu J, Gullett JM, Kanneganti TD. Pathogens 11 1400 (2022)
  48. Improving attrition rates in Ebola virus drug discovery. Glisic S, Paessler S, Veljkovic N, Perovic VR, Prljic J, Veljkovic V. Expert Opin Drug Discov 10 1025-1032 (2015)
  49. Investigating the Interaction between Negative Strand RNA Viruses and Their Hosts for Enhanced Vaccine Development and Production. Mara K, Dai M, Brice AM, Alexander MR, Tribolet L, Layton DS, Bean AGD. Vaccines (Basel) 9 59 (2021)
  50. Nuclear transport proteins: structure, function, and disease relevance. Yang Y, Guo L, Chen L, Gong B, Jia D, Sun Q. Signal Transduct Target Ther 8 425 (2023)

Articles citing this publication (75)

  1. MSAViewer: interactive JavaScript visualization of multiple sequence alignments. Yachdav G, Wilzbach S, Rauscher B, Sheridan R, Sillitoe I, Procter J, Lewis SE, Rost B, Goldberg T. Bioinformatics 32 3501-3503 (2016)
  2. Protein Interaction Mapping Identifies RBBP6 as a Negative Regulator of Ebola Virus Replication. Batra J, Hultquist JF, Liu D, Shtanko O, Von Dollen J, Satkamp L, Jang GM, Luthra P, Schwarz TM, Small GI, Arnett E, Anantpadma M, Reyes A, Leung DW, Kaake R, Haas P, Schmidt CB, Schlesinger LS, LaCount DJ, Davey RA, Amarasinghe GK, Basler CF, Krogan NJ. Cell 175 1917-1930.e13 (2018)
  3. Differential Regulation of Interferon Responses by Ebola and Marburg Virus VP35 Proteins. Edwards MR, Liu G, Mire CE, Sureshchandra S, Luthra P, Yen B, Shabman RS, Leung DW, Messaoudi I, Geisbert TW, Amarasinghe GK, Basler CF. Cell Rep 14 1632-1640 (2016)
  4. Topoisomerase II Inhibitors Induce DNA Damage-Dependent Interferon Responses Circumventing Ebola Virus Immune Evasion. Luthra P, Aguirre S, Yen BC, Pietzsch CA, Sanchez-Aparicio MT, Tigabu B, Morlock LK, García-Sastre A, Leung DW, Williams NS, Fernandez-Sesma A, Bukreyev A, Basler CF. mBio 8 e00368-17 (2017)
  5. Inhibiting pyrimidine biosynthesis impairs Ebola virus replication through depletion of nucleoside pools and activation of innate immune responses. Luthra P, Naidoo J, Pietzsch CA, De S, Khadka S, Anantpadma M, Williams CG, Edwards MR, Davey RA, Bukreyev A, Ready JM, Basler CF. Antiviral Res 158 288-302 (2018)
  6. STAT2 Is a Pervasive Cytokine Regulator due to Its Inhibition of STAT1 in Multiple Signaling Pathways. Ho J, Pelzel C, Begitt A, Mee M, Elsheikha HM, Scott DJ, Vinkemeier U. PLoS Biol 14 e2000117 (2016)
  7. Enterovirus 71 suppresses interferon responses by blocking Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling through inducing karyopherin-α1 degradation. Wang C, Sun M, Yuan X, Ji L, Jin Y, Cardona CJ, Xing Z. J Biol Chem 292 10262-10274 (2017)
  8. Electron Cryo-microscopy Structure of Ebola Virus Nucleoprotein Reveals a Mechanism for Nucleocapsid-like Assembly. Su Z, Wu C, Shi L, Luthra P, Pintilie GD, Johnson B, Porter JR, Ge P, Chen M, Liu G, Frederick TE, Binning JM, Bowman GR, Zhou ZH, Basler CF, Gross ML, Leung DW, Chiu W, Amarasinghe GK. Cell 172 966-978.e12 (2018)
  9. Differential transcriptional responses to Ebola and Marburg virus infection in bat and human cells. Hölzer M, Krähling V, Amman F, Barth E, Bernhart SH, Carmelo VA, Collatz M, Doose G, Eggenhofer F, Ewald J, Fallmann J, Feldhahn LM, Fricke M, Gebauer J, Gruber AJ, Hufsky F, Indrischek H, Kanton S, Linde J, Mostajo N, Ochsenreiter R, Riege K, Rivarola-Duarte L, Sahyoun AH, Saunders SJ, Seemann SE, Tanzer A, Vogel B, Wehner S, Wolfinger MT, Backofen R, Gorodkin J, Grosse I, Hofacker I, Hoffmann S, Kaleta C, Stadler PF, Becker S, Marz M. Sci Rep 6 34589 (2016)
  10. Hepatitis B Virus Precore Protein p22 Inhibits Alpha Interferon Signaling by Blocking STAT Nuclear Translocation. Mitra B, Wang J, Kim ES, Mao R, Dong M, Liu Y, Zhang J, Guo H. J Virol 93 e00196-19 (2019)
  11. A Rapid Screening Assay Identifies Monotherapy with Interferon-ß and Combination Therapies with Nucleoside Analogs as Effective Inhibitors of Ebola Virus. McCarthy SD, Majchrzak-Kita B, Racine T, Kozlowski HN, Baker DP, Hoenen T, Kobinger GP, Fish EN, Branch DR. PLoS Negl Trop Dis 10 e0004364 (2016)
  12. Different Temporal Effects of Ebola Virus VP35 and VP24 Proteins on Global Gene Expression in Human Dendritic Cells. Ilinykh PA, Lubaki NM, Widen SG, Renn LA, Theisen TC, Rabin RL, Wood TG, Bukreyev A. J Virol 89 7567-7583 (2015)
  13. Structural basis for importin alpha 3 specificity of W proteins in Hendra and Nipah viruses. Smith KM, Tsimbalyuk S, Edwards MR, Cross EM, Batra J, Soares da Costa TP, Aragão D, Basler CF, Forwood JK. Nat Commun 9 3703 (2018)
  14. The Methyltransferase-Like Domain of Chikungunya Virus nsP2 Inhibits the Interferon Response by Promoting the Nuclear Export of STAT1. Göertz GP, McNally KL, Robertson SJ, Best SM, Pijlman GP, Fros JJ. J Virol 92 e01008-18 (2018)
  15. Three-dimensional context rather than NLS amino acid sequence determines importin α subtype specificity for RCC1. Sankhala RS, Lokareddy RK, Begum S, Pumroy RA, Gillilan RE, Cingolani G. Nat Commun 8 979 (2017)
  16. Elucidating variations in the nucleotide sequence of Ebola virus associated with increasing pathogenicity. Dowall SD, Matthews DA, Garcia-Dorival I, Taylor I, Kenny J, Hertz-Fowler C, Hall N, Corbin-Lickfett K, Empig C, Schlunegger K, Barr JN, Carroll MW, Hewson R, Hiscox JA. Genome Biol 15 540 (2014)
  17. A single phosphorodiamidate morpholino oligomer targeting VP24 protects rhesus monkeys against lethal Ebola virus infection. Warren TK, Whitehouse CA, Wells J, Welch L, Heald AE, Charleston JS, Sazani P, Reid SP, Iversen PL, Bavari S. mBio 6 e02344-14 (2015)
  18. Systematic Genome-wide Screening and Prediction of microRNAs in EBOV During the 2014 Ebolavirus Outbreak. Teng Y, Wang Y, Zhang X, Liu W, Fan H, Yao H, Lin B, Zhu P, Yuan W, Tong Y, Cao W. Sci Rep 5 9912 (2015)
  19. Lloviu virus VP24 and VP35 proteins function as innate immune antagonists in human and bat cells. Feagins AR, Basler CF. Virology 485 145-152 (2015)
  20. The methyltransferase domain of the Sudan ebolavirus L protein specifically targets internal adenosines of RNA substrates, in addition to the cap structure. Martin B, Coutard B, Guez T, Paesen GC, Canard B, Debart F, Vasseur JJ, Grimes JM, Decroly E. Nucleic Acids Res 46 7902-7912 (2018)
  21. Crystal Structure of Marburg Virus VP40 Reveals a Broad, Basic Patch for Matrix Assembly and a Requirement of the N-Terminal Domain for Immunosuppression. Oda S, Noda T, Wijesinghe KJ, Halfmann P, Bornholdt ZA, Abelson DM, Armbrust T, Stahelin RV, Kawaoka Y, Saphire EO. J Virol 90 1839-1848 (2016)
  22. HIV-1 Vpr antagonizes innate immune activation by targeting karyopherin-mediated NF-κB/IRF3 nuclear transport. Khan H, Sumner RP, Rasaiyaah J, Tan CP, Rodriguez-Plata MT, Van Tulleken C, Fink D, Zuliani-Alvarez L, Thorne L, Stirling D, Milne RS, Towers GJ. Elife 9 e60821 (2020)
  23. Porcine bocavirus NP1 negatively regulates interferon signaling pathway by targeting the DNA-binding domain of IRF9. Zhang R, Fang L, Wang D, Cai K, Zhang H, Xie L, Li Y, Chen H, Xiao S. Virology 485 414-421 (2015)
  24. Virus-encoded miRNAs in Ebola virus disease. Duy J, Honko AN, Altamura LA, Bixler SL, Wollen-Roberts S, Wauquier N, O'Hearn A, Mucker EM, Johnson JC, Shamblin JD, Zelko J, Botto MA, Bangura J, Coomber M, Pitt ML, Gonzalez JP, Schoepp RJ, Goff AJ, Minogue TD. Sci Rep 8 6480 (2018)
  25. Ebola virus encodes a miR-155 analog to regulate importin-α5 expression. Liu Y, Sun J, Zhang H, Wang M, Gao GF, Li X. Cell Mol Life Sci 73 3733-3744 (2016)
  26. Effects of Filovirus Interferon Antagonists on Responses of Human Monocyte-Derived Dendritic Cells to RNA Virus Infection. Yen BC, Basler CF. J Virol 90 5108-5118 (2016)
  27. Importin α1 is required for nuclear import of herpes simplex virus proteins and capsid assembly in fibroblasts and neurons. Döhner K, Ramos-Nascimento A, Bialy D, Anderson F, Hickford-Martinez A, Rother F, Koithan T, Rudolph K, Buch A, Prank U, Binz A, Hügel S, Lebbink RJ, Hoeben RC, Hartmann E, Bader M, Bauerfeind R, Sodeik B. PLoS Pathog 14 e1006823 (2018)
  28. Importin β1 targeting by hepatitis C virus NS3/4A protein restricts IRF3 and NF-κB signaling of IFNB1 antiviral response. Gagné B, Tremblay N, Park AY, Baril M, Lamarre D. Traffic 18 362-377 (2017)
  29. Improvements to the ABSINTH Force Field for Proteins Based on Experimentally Derived Amino Acid Specific Backbone Conformational Statistics. Choi JM, Pappu RV. J Chem Theory Comput 15 1367-1382 (2019)
  30. Macrocyclic peptide inhibitors for the protein-protein interaction of Zaire Ebola virus protein 24 and karyopherin alpha 5. Song X, Lu LY, Passioura T, Suga H. Org Biomol Chem 15 5155-5160 (2017)
  31. Fas-Associated Factor 1 Negatively Regulates the Antiviral Immune Response by Inhibiting Translocation of Interferon Regulatory Factor 3 to the Nucleus. Song S, Lee JJ, Kim HJ, Lee JY, Chang J, Lee KJ. Mol Cell Biol 36 1136-1151 (2016)
  32. Structural basis for nuclear import selectivity of pioneer transcription factor SOX2. Jagga B, Edwards M, Pagin M, Wagstaff KM, Aragão D, Roman N, Nanson JD, Raidal SR, Dominado N, Stewart M, Jans DA, Hime GR, Nicolis SK, Basler CF, Forwood JK. Nat Commun 12 28 (2021)
  33. Amino Acid Residue at Position 79 of Marburg Virus VP40 Confers Interferon Antagonism in Mouse Cells. Feagins AR, Basler CF. J Infect Dis 212 Suppl 2 S219-25 (2015)
  34. The Ebola virus VP35 protein binds viral immunostimulatory and host RNAs identified through deep sequencing. Dilley KA, Voorhies AA, Luthra P, Puri V, Stockwell TB, Lorenzi H, Basler CF, Shabman RS. PLoS One 12 e0178717 (2017)
  35. Assessing the contribution of interferon antagonism to the virulence of West African Ebola viruses. Dunham EC, Banadyga L, Groseth A, Chiramel AI, Best SM, Ebihara H, Feldmann H, Hoenen T. Nat Commun 6 8000 (2015)
  36. Ebolavirus classification based on natural vectors. Zheng H, Yin C, Hoang T, He RL, Yang J, Yau SS. DNA Cell Biol 34 418-428 (2015)
  37. Marburg Virus VP24 Protein Relieves Suppression of the NF-κB Pathway Through Interaction With Kelch-like ECH-Associated Protein 1. Edwards MR, Basler CF. J Infect Dis 212 Suppl 2 S154-9 (2015)
  38. Targeting Importin-α7 as a Therapeutic Approach against Pandemic Influenza Viruses. Resa-Infante P, Paterson D, Bonet J, Otte A, Oliva B, Fodor E, Gabriel G. J Virol 89 9010-9020 (2015)
  39. Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus. Lai KY, Ng WY, Cheng FF. Infect Dis Poverty 3 43 (2014)
  40. Nuclear-localized human respiratory syncytial virus NS1 protein modulates host gene transcription. Pei J, Beri NR, Zou AJ, Hubel P, Dorando HK, Bergant V, Andrews RD, Pan J, Andrews JM, Sheehan KCF, Pichlmair A, Amarasinghe GK, Brody SL, Payton JE, Leung DW. Cell Rep 37 109803 (2021)
  41. Regulation of the Ebola Virus VP24 Protein by SUMO. Vidal S, El Motiam A, Seoane R, Preitakaite V, Bouzaher YH, Gómez-Medina S, San Martín C, Rodríguez D, Rejas MT, Baz-Martínez M, Barrio R, Sutherland JD, Rodríguez MS, Muñoz-Fontela C, Rivas C. J Virol 94 e01687-19 (2019)
  42. Impact of Měnglà Virus Proteins on Human and Bat Innate Immune Pathways. Williams CG, Gibbons JS, Keiffer TR, Luthra P, Edwards MR, Basler CF. J Virol 94 e00191-20 (2020)
  43. Pathogenicity and Virulence of Ebolaviruses with Species- and Variant-specificity. Yamaoka S, Ebihara H. Virulence 12 885-901 (2021)
  44. Pathophysiology of Ebola Virus Infection: Current Challenges and Future Hopes. Rivera A, Messaoudi I. ACS Infect Dis 1 186-197 (2015)
  45. Importin-α7 Is Involved in the Formation of Ebola Virus Inclusion Bodies but Is Not Essential for Pathogenicity in Mice. Gabriel G, Feldmann F, Reimer R, Thiele S, Fischer M, Hartmann E, Bader M, Ebihara H, Hoenen T, Feldmann H. J Infect Dis 212 Suppl 2 S316-21 (2015)
  46. Possible FDA-approved drugs to treat Ebola virus infection. Yuan S. Infect Dis Poverty 4 23 (2015)
  47. The Integrity of the YxxL Motif of Ebola Virus VP24 Is Important for the Transport of Nucleocapsid-Like Structures and for the Regulation of Viral RNA Synthesis. Takamatsu Y, Kolesnikova L, Schauflinger M, Noda T, Becker S. J Virol 94 e02170-19 (2020)
  48. Development of oligonucleotide-based antagonists of Ebola virus protein 24 inhibiting its interaction with karyopherin alpha 1. Tanaka K, Kasahara Y, Miyamoto Y, Okuda T, Kasai T, Onodera K, Kuwahara M, Oka M, Yoneda Y, Obika S. Org Biomol Chem 16 4456-4463 (2018)
  49. Global phosphoproteomic analysis of Ebola virions reveals a novel role for VP35 phosphorylation-dependent regulation of genome transcription. Ivanov A, Ramanathan P, Parry C, Ilinykh PA, Lin X, Petukhov M, Obukhov Y, Ammosova T, Amarasinghe GK, Bukreyev A, Nekhai S. Cell Mol Life Sci 77 2579-2603 (2020)
  50. Large-scale data-driven integrative framework for extracting essential targets and processes from disease-associated gene data sets. Mazandu GK, Chimusa ER, Rutherford K, Zekeng EG, Gebremariam ZZ, Onifade MY, Mulder NJ. Brief Bioinform 19 1141-1152 (2018)
  51. Development and Validation of a Novel Dual Luciferase Reporter Gene Assay to Quantify Ebola Virus VP24 Inhibition of IFN Signaling. Fanunza E, Frau A, Sgarbanti M, Orsatti R, Corona A, Tramontano E. Viruses 10 E98 (2018)
  52. Genome-wide profiling of microRNAs reveals novel insights into the interactions between H9N2 avian influenza virus and avian dendritic cells. Lin J, Xia J, Zhang T, Zhang K, Yang Q. Oncogene 37 4562-4580 (2018)
  53. Structure of IMPORTIN-4 bound to the H3-H4-ASF1 histone-histone chaperone complex. Bernardes NE, Fung HYJ, Li Y, Chen Z, Chook YM. Proc Natl Acad Sci U S A 119 e2207177119 (2022)
  54. An all-atom molecular dynamics study of the anti-interferon signaling of Ebola virus: interaction mechanisms of EBOV VP24 binding to Karyopherin alpha5. Ding JN, Zhang YJ, Zhong H, Ao CC, Li J, Han JG. Mol Biosyst 13 1031-1045 (2017)
  55. Comparative study of the interactions between fungal transcription factor nuclear localization sequences with mammalian and fungal importin-alpha. Bernardes NE, Fukuda CA, da Silva TD, de Oliveira HC, de Barros AC, Dreyer TR, Bertolini MC, Fontes MRM. Sci Rep 10 1458 (2020)
  56. Antagonism of STAT3 signalling by Ebola virus. Harrison AR, Todd S, Dearnley M, David CT, Green D, Rawlinson SM, Au GG, Marsh GA, Moseley GW. PLoS Pathog 17 e1009636 (2021)
  57. Changes associated with Ebola virus adaptation to novel species. Pappalardo M, Reddin IG, Cantoni D, Rossman JS, Michaelis M, Wass MN. Bioinformatics 33 1911-1915 (2017)
  58. Filovirus VP24 Proteins Differentially Regulate RIG-I and MDA5-Dependent Type I and III Interferon Promoter Activation. He FB, Khan H, Huttunen M, Kolehmainen P, Melén K, Maljanen S, Qu M, Jiang M, Kakkola L, Julkunen I. Front Immunol 12 694105 (2021)
  59. MERS-CoV ORF4b employs an unusual binding mechanism to target IMPα and block innate immunity. Munasinghe TS, Edwards MR, Tsimbalyuk S, Vogel OA, Smith KM, Stewart M, Foster JK, Bosence LA, Aragão D, Roby JA, Basler CF, Forwood JK. Nat Commun 13 1604 (2022)
  60. Against Ebola: type I interferon guard risk and mesenchymal stromal cell combat sepsis. Zhang L, Wang H, Zhang YQ. J Zhejiang Univ Sci B 16 1-9 (2015)
  61. The Ebola Virus Interferon Antagonist VP24 Undergoes Active Nucleocytoplasmic Trafficking. Harrison AR, David CT, Rawlinson SM, Moseley GW. Viruses 13 1650 (2021)
  62. The PDB database is a rich source of alpha-helical anti-microbial peptides to combat disease causing pathogens. Chakraborty S, Phu M, de Morais TP, Nascimento R, Goulart LR, Rao BJ, Asgeirsson B, Dandekar AM. F1000Res 3 295 (2014)
  63. Structural and mechanistic insights into nuclear transport and delivery of the critical pluripotency factor Oct4 to DNA. Okuyama T, Yamagishi R, Shimada J, Ikeda M, Maruoka Y, Kaneko H. J Biomol Struct Dyn 36 767-778 (2018)
  64. A simulation investigation on interaction mechanism between Ebola nucleoprotein and VP35 peptide. Ding JN, Zhang YJ, Zhong H, Ao CC, Han JG. J Biomol Struct Dyn 36 1009-1028 (2018)
  65. Avian Metapneumovirus Subgroup C Phosphoprotein Suppresses Type I Interferon Production by Blocking Interferon Regulatory Factor 3 Nuclear Translocation. Hou L, Shi Y, Guo J, Sun T, Wang D, Yang X, Liu C, Cui Y, Zhu N, Tong X, Pan Y, Feng X, Zhou J, Liu J. Microbiol Spectr 11 e0341322 (2023)
  66. DOCLASP - Docking ligands to target proteins using spatial and electrostatic congruence extracted from a known holoenzyme and applying simple geometrical transformations. Chakraborty S. F1000Res 3 262 (2014)
  67. Ebola update. Nunes-Alves C. Nat Rev Microbiol 12 656 (2014)
  68. High-Throughput Screening Assay to Identify Small Molecule Inhibitors of Marburg Virus VP40 Protein. Luthra P, Anantpadma M, De S, Sourimant J, Davey RA, Plemper RK, Basler CF. ACS Infect Dis 6 2783-2799 (2020)
  69. Porcine Circovirus Type 2 Hijacks Host IPO5 to Sustain the Intracytoplasmic Stability of Its Capsid Protein. Lin C, Hu J, Dai Y, Zhang H, Xu K, Dong W, Yan Y, Peng X, Zhou J, Gu J. J Virol 96 e0152222 (2022)
  70. The Minor Matrix Protein VP24 from Ebola Virus Lacks Direct Lipid-Binding Properties. Su Y, Stahelin RV. Viruses 12 E869 (2020)
  71. ADAP restraint of STAT1 signaling regulates macrophage phagocytosis in immune thrombocytopenia. Xiong Y, Li Y, Cui X, Zhang L, Yang X, Liu H. Cell Mol Immunol 19 898-912 (2022)
  72. Ebolavirus Species-Specific Interferon Antagonism Mediated by VP24. Ramanathan P, Tigabu B, Santos RI, Ilinykh PA, Kuzmina N, Vogel OA, Thakur N, Ahmed H, Wu C, Amarasinghe GK, Basler CF, Bukreyev A. Viruses 15 1075 (2023)
  73. Inhibiting the transcription and replication of Ebola viruses by disrupting the nucleoprotein and VP30 protein interaction with small molecules. Ma YH, Hong X, Wu F, Xu XF, Li R, Zhong J, Zhou YQ, Liu SW, Zhan J, Xu W. Acta Pharmacol Sin 44 1487-1499 (2023)
  74. Noncanonical Rab9a action supports retromer-mediated endosomal exit of human papillomavirus during virus entry. Choi J, DiMaio D. PLoS Pathog 19 e1011648 (2023)
  75. Letter Potential Ebola prophylaxis. Feller JM. J Paediatr Child Health 51 743 (2015)


Quick links